Pretreatment stromal CD4⁺ T-cell density predicts favorable response to total neoadjuvant therapy in locally advanced rectal cancer
Abstract
Total neoadjuvant therapy (TNT) has become an important treatment strategy for locally advanced rectal cancer (LARC), increasing the need for pretreatment biomarkers that may predict major tumor response and support organ-preserving approaches. This study aimed to evaluate whether pretreatment stromal CD4⁺ and CD8⁺ T-cell densities, together with stromal tumor-infiltrating lymphocytes (TILs), are associated with response to TNT in patients with LARC. In this retrospective study, 45 patients with LARC who completed TNT were analyzed; pretreatment colonoscopic biopsy specimens were available for all patients, and paired post-treatment resection specimens were available for 40 surgically treated patients. CD4⁺ and CD8⁺ T-cell densities were assessed immunohistochemically in stromal hotspot areas and expressed as cells/mm², while stromal TILs were evaluated on hematoxylin–eosin sections. A favorable response was defined as tumor regression grade (TRG) 0–1 in surgically treated patients or clinical complete response in patients managed with a watch-and-wait strategy. Median pretreatment CD4⁺ T-cell density, CD8⁺ T-cell density, and stromal TIL percentage were 320 cells/mm², 64 cells/mm², and 30%, respectively. Receiver operating characteristic (ROC) analysis identified a pretreatment stromal CD4⁺ T-cell density cutoff of 410 cells/mm² for favorable response, with an area under the curve (AUC) of 0.68 (p=0.041). CD4⁺ T-cell density >410 cells/mm² was significantly associated with favorable response and remained independently associated with response in multivariable logistic regression analysis (odds ratio [OR]=5.05, 95% confidence interval [CI]: 1.21–20.83, p=0.026). In contrast, pretreatment CD8⁺ T-cell density and stromal TIL percentage were not significantly associated with response. In paired specimens, CD8⁺ T-cell density increased significantly after treatment (p<0.001), whereas CD4⁺ T-cell density and stromal TIL percentage did not change significantly. Lymphovascular invasion (LVI) and perineural invasion (PNI) were associated with non-favorable response. High pretreatment stromal CD4⁺ T-cell density may represent a candidate biomarker of favorable response to TNT in LARC, while the post-treatment increase in CD8⁺ T-cell density suggests a potential immunomodulatory effect of TNT; however, prospective validation in larger cohorts is required.
Keywords
CD4 CD8 locally advanced rectal cancer neoadjuvant therapy TIL tumor regression gradeDownloads
References
Guida AM, Sensi B, Formica V, D'Angelillo RM, Roselli M, Del Vecchio Blanco G, Rossi P, Capolupo GT, Caricato M, Sica GS. Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview. Biol Direct. 2022;17(1):16. https://doi.org/10.1186/s13062-022-00329-7 DOI: https://doi.org/10.1186/s13062-022-00329-7
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80. https://doi.org/10.1016/S0140-6736(19)32319-0 DOI: https://doi.org/10.1016/S0140-6736(19)32319-0
Srivastava V, Goswami AG, Basu S, Shukla VK. Locally advanced rectal cancer: what we learned in the last two decades and the future perspectives. J Gastrointest Cancer. 2023;54(1):188–203. https://doi.org/10.1007/s12029-021-00794-9 DOI: https://doi.org/10.1007/s12029-021-00794-9
Kasi A, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J, Sun W. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(12). https://doi.org/10.1001/jamanetworkopen.2020.30097 DOI: https://doi.org/10.1001/jamanetworkopen.2020.30097
Turri G, Ostuzzi G, Vita G, Barresi V, Scarpa A, Milella M, Mazzarotto R, Ruzzenente A, Barbui C, Pedrazzani C. Treatment of locally advanced rectal cancer in the era of total neoadjuvant therapy: a systematic review and network meta-analysis. JAMA Netw Open. 2024;7(6). https://doi.org/10.1001/jamanetworkopen.2024.14702 DOI: https://doi.org/10.1001/jamanetworkopen.2024.14702
Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Putter H, Berglund Å, Cervantes A, Crolla RMPH, Hendriks MP, Capdevila J, Edhemovic I, Marijnen CAM, van de Velde CJH, Glimelius B, van Etten B; Collaborative Investigators. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg. 2023;278(4)–72. https://doi.org/10.1097/SLA.0000000000005799 DOI: https://doi.org/10.1097/SLA.0000000000005799
Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42. https://doi.org/10.1016/S1470-2045(20)30555-6 DOI: https://doi.org/10.1016/S1470-2045(20)30555-6
O'Brien T, Hospers G, Conroy T, Lenz HJ, Smith JJ, Andrews E, O'Neill B, Leonard G. The role of total neoadjuvant therapy in locally advanced rectal cancer: a survey of specialists attending the All-Ireland Colorectal Cancer Conference 2022 including lead investigators of OPRA, PRODIGE-23 and RAPIDO. Ir J Med Sci. 2024;193(3):1183–90. https://doi.org/10.1007/s11845-023-03591-4 DOI: https://doi.org/10.1007/s11845-023-03591-4
Chehade L, Dagher K, Shamseddine A. Tailoring treatment for locally advanced rectal cancer. Cancer Treat Res Commun. 2024;41:100847. https://doi.org/10.1016/j.ctarc.2024.100847 DOI: https://doi.org/10.1016/j.ctarc.2024.100847
Aghili M, Aghaei MM, Abyaneh R, Babaei M, Farhan F, Lashkari M, Farazmand B, Kolahdouzan K, Piozzi GN, Counago F, Ghalehtaki R. Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: long-term results of a randomized controlled trial. Int J Colorectal Dis. 2025;40(1):118. https://doi.org/10.1007/s00384-025-04901-1 DOI: https://doi.org/10.1007/s00384-025-04901-1
Wu Z, Zheng Y, Sheng J, Han Y, Yang Y, Pan H, Yao J. CD3⁺CD4⁻CD8⁻ double-negative T cells in inflammation, immune disorders and cancer. Front Immunol. 2022;13:816005. https://doi.org/10.3389/fimmu.2022.816005 DOI: https://doi.org/10.3389/fimmu.2022.816005
Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, Melcher AA. The immune system—is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol). 2008;20(2):101–12. https://doi.org/10.1016/j.clon.2007.10.011 DOI: https://doi.org/10.1016/j.clon.2007.10.011
Tong Q, Liu K, Wang G. FasL expression in colorectal carcinoma and its significance in immune escape of cancer. J Huazhong Univ Sci Technolog Med Sci. 2006;26(1):79–81. https://doi.org/10.1007/BF02828044 DOI: https://doi.org/10.1007/BF02828044
Shinto E, Omata J, Sikina A, Sekizawa A, Kajiwara Y, Hayashi K, Hashiguchi Y, Hase K, Ueno H. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer. BJS Open. 2020;4(2):301–9. https://doi.org/10.1002/bjs5.50251 DOI: https://doi.org/10.1002/bjs5.50251
Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci. 2013;1284(1):1–5. https://doi.org/10.1111/nyas.12105 DOI: https://doi.org/10.1111/nyas.12105
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400–4. https://doi.org/10.1038/nature10755 DOI: https://doi.org/10.1038/nature10755
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC cancer staging manual. 8th ed. Cham: Springer; 2017.
Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546–56. https://doi.org/10.1200/JCO.22.00032 DOI: https://doi.org/10.1200/JCO.22.00032
College of American Pathologists. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Version 4.0.1.0. Northfield: College of American Pathologists; 2017. https://documents.cap.org/protocols/cp-gilower-colonrectum-17protocol-4010.pdf
Fokas E, Williams H, Diefenhardt M, Lin S, Qin LX, Piso P, Dapper H, Germer CT, Grützmann R, Friede T, Smith JJ, Saltz LB, Wu AJ, Weiser MR, Omer D, Ghadimi M, Hofheinz RD, Garcia-Aguilar J, Rödel C; German Rectal Cancer Study Group and the OPRA Consortium. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials. Eur J Cancer. 2024;210:114291. https://doi.org/10.1016/j.ejca.2024.114291 DOI: https://doi.org/10.1016/j.ejca.2024.114291
Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–15. https://doi.org/10.1016/S1470-2045(21)00079-6 DOI: https://doi.org/10.1016/S1470-2045(21)00079-6
Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, Thompson HM, Yuval JB, Kim JK, Dunne RF, Marcet J, Cataldo P, Polite B, Herzig DO, Liska D, Oommen S, Friel CM, Ternent C, Coveler AL, Hunt S, Gregory A, Varma MG, Bello BL, Carmichael JC, Krauss J, Gleisner A, Guillem JG, Temple L, Goodman KA, Segal NH, Cercek A, Yaeger R, Nash GM, Widmar M, Wei IH, Pappou EP, Weiser MR, Paty PB, Smith JJ, Wu AJ, Gollub MJ, Saltz LB, Garcia-Aguilar J. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol. 2024;42(5):500–6. https://doi.org/10.1200/JCO.23.01208 DOI: https://doi.org/10.1200/JCO.23.01208
Chen HY, Feng LL, Li M, Ju HQ, Ding Y, Lan M, Song SM, Han WD, Yu L, Wei MB, Pang XL, He F, Liu S, Zheng J, Ma Y, Lin CY, Lan P, Huang MJ, Zou YF, Yang ZL, Wang T, Lang JY, Orangio GR, Poylin V, Ajani JA, Wang WH, Wan XB. College of American Pathologists tumor regression grading system for long-term outcome in patients with locally advanced rectal cancer. Oncologist. 2021;26(5)–93. https://doi.org/10.1002/onco.13707 DOI: https://doi.org/10.1002/onco.13707
Lu X, Qi R, Xu Y, Wang X, Cai Y, Wang C. Tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: influencing factors and prognostic significance. Int J Clin Exp Pathol. 2023;16(6):124–32.
· Inoue A, Kagawa Y, Nishizawa Y, Komori T, Hashimoto M, Ozato Y, Morimoto Y, Shimamoto S, Miyazaki Y, Tomokuni A, Motoori M, Fujitani K. Outcomes of neoadjuvant chemoradiotherapy for locally advanced rectal cancer under non-smoking conditions confirmed by measuring expiratory CO levels: an observational study. Oncol Lett. 2025;29(6):266. https://doi.org/10.3892/ol.2025.15012 DOI: https://doi.org/10.3892/ol.2025.15012
Chuang JP, Tsai HL, Chen PJ, Huang CW, Su WC, Chang TK, Chen YC, Li CC, Yeh YS, Wang JY. Smoking and elevated preneoadjuvant chemoradiotherapy serum carcinoembryonic antigen levels are associated with high tumor regression grade and poor survival in patients with locally advanced rectal cancer. Kaohsiung J Med Sci. 2025;41(6). https://doi.org/10.1002/kjm2.70008 DOI: https://doi.org/10.1002/kjm2.70008
Morini A, Annicchiarico A, Romboli A, Ricco' M, Crafa P, Montali F, Dell'Abate P, Costi R. Retrospective survival analysis of stage II–III rectal cancer: tumour regression grade, grading and lymphovascular invasion are the only predictors. ANZ J Surg. 2021;91(3)–18. https://doi.org/10.1111/ans.16476 DOI: https://doi.org/10.1111/ans.16476
Laohawiriyakamol S, Chaochankit W, Wanichsuwan W, Kanjanapradit K, Laohawiriyakamol T. An investigation into tumor regression grade as a parameter for locally advanced rectal cancer and 5-year overall survival rate. Ann Coloproctol. 2023;39(1):59–70. DOI: https://doi.org/10.3393/ac.2021.01011.0144
Bhutiani N, Yousef MM, Yousef AM, Haque EU, Chang GJ, Konishi T, Bednarski BK, You YN, Shen JP, Uppal A. Does extramural vascular invasion predict response to neoadjuvant therapy in locally advanced rectal cancer? Clin Colorectal Cancer. 2025;24(2):272–279.e2. https://doi.org/10.1016/j.clcc.2025.02.002 DOI: https://doi.org/10.1016/j.clcc.2025.02.002
Xu Y, Lou X, Liang Y, Zhang S, Yang S, Chen Q, Xu Z, Zhao M, Li Z, Zhao K, Liu Z. Predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer using tumor-infiltrating lymphocytes density. J Inflamm Res. 2021;14:5891–9. https://doi.org/10.2147/JIR.S342214 DOI: https://doi.org/10.2147/JIR.S342214
Mohammed A, Bakry A, Gharieb S, Hanna A, Obaya A, Abdelhady W, Metwalli A. Predictive value of tumor-infiltrating lymphocytes and Ki-67 for pathological response to total neoadjuvant therapy in rectal cancer. J Gastrointest Cancer. 2024;55(2):869–76. https://doi.org/10.1007/s12029-024-01026-6 DOI: https://doi.org/10.1007/s12029-024-01026-6
Fan S, Zhao Z, Meng Q, Wang H, Yu B, Niu W. Immune activation following PD-L1 inhibitor plus chemoradiotherapy in locally advanced rectal cancer: a retrospective, single-arm study. Front Immunol. 2025;16:1619043. https://doi.org/10.3389/fimmu.2025.1619043 DOI: https://doi.org/10.3389/fimmu.2025.1619043
Schollbach J, Kircher S, Wiegering A, Seyfried F, Klein I, Rosenwald A, Germer CT, Löb S. Prognostic value of tumour-infiltrating CD8⁺ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe? Cancer Immunol Immunother. 2019;68(4):563–75. https://doi.org/10.1007/s00262-019-02306-y DOI: https://doi.org/10.1007/s00262-019-02306-y
Zaghloul H, Abbas A, Abdulah D. Tumor microenvironment mediators CD8⁺- and FOXP3⁺-labeled T lymphocytes are prospective prognosticators in curatively treated rectal cancer patients. J Gastrointest Cancer. 2021;52(1):177–86. https://doi.org/10.1007/s12029-020-00376-1 DOI: https://doi.org/10.1007/s12029-020-00376-1
Lai S, Lou X, Fan X, Sun W, Deng Y, Wang J, Huang Y, Dou R. Density and distribution of lymphocytes in pretherapeutic rectal cancer and response to neoadjuvant therapy. Gastroenterol Rep (Oxf). 2020;8(6):445–52. https://doi.org/10.1093/gastro/goaa016 DOI: https://doi.org/10.1093/gastro/goaa016
Orhan A, Khesrawi F, Tvilling Madsen M, Peuliche Vogelsang R, Dohrn N, Kanstrup Fiehn AM, Gögenur I. Tumor-infiltrating lymphocytes as biomarkers of treatment response and long-term survival in patients with rectal cancer: a systematic review and meta-analysis. Cancers (Basel). 2022;14(3):636. https://doi.org/10.3390/cancers14030636 DOI: https://doi.org/10.3390/cancers14030636
Malekzadeh Moghani M, Alahyari S, Moradi A, Nasiri M. Pathological predictors of response to neoadjuvant treatment in rectal carcinoma. J Gastrointest Cancer. 2021;52(2):690–5. DOI: https://doi.org/10.1007/s12029-020-00450-8
Matsutani S, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S, Hirakawa K, Ohira M. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer. Cancer Sci. 2018;109(4):966–79. https://doi.org/10.1111/cas.13542 DOI: https://doi.org/10.1111/cas.13542
Akiyoshi T, Tanaka N, Kiyotani K, Gotoh O, Yamamoto N, Oba K, Fukunaga Y, Ueno M, Mori S. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg. 2019;106(10):1381–92. https://doi.org/10.1002/bjs.11179 DOI: https://doi.org/10.1002/bjs.11179
Niu W, Wu F, Liu Y, Zhou C, Zhang J, Hu X, Li B, Wang G. Neoadjuvant chemoradiotherapy for treatment of locally advanced rectal cancer: efficacy and tumor immune microenvironment changes. Chin J Clin Oncol. 2023;17(5):519–23.
Article files
Publication details
- Citation
- Advance online
- Language
- EN
- License
- CC BY 4.0
- Section
- Research article
How to cite (Vancouver)
Telci H, Goktas Aydin S, Erkinuresin T, Tasan SC, Ozluk E, Bozdag E, et al. Pretreatment stromal CD4⁺ T-cell density predicts favorable response to total neoadjuvant therapy in locally advanced rectal cancer. Biomol Biomed. 2026. https://doi.org/10.17305/bb.2026.14270





